Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 plus D-1553 in KRAS G12C-mutated solid tumors
NCT06435455Phase 2Not yet recruiting
- Sponsor
- Genhouse Bio
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of GH21 in Solid tumors, sponsored by Genhouse Bio. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
GH21
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT06435455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435455.